里桑基祖马布在克罗恩病患者的长期有效性和安全性
Adar Zinger1, David Choi1, Natalie Choi1
1Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, Illinois.
概括
这项研究表明,瑞桑基祖马布在长期治疗克罗恩氏病 (CD) 中是有效和安全的. 现实世界的数据表明,先前用乌斯特基努马布治疗的患者的结果与此相似.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 克罗恩氏病 (CD) 是一种慢性炎症性肠病.
- 瑞桑基祖马布是一种被批准用于CD治疗的互白素-23抑制剂.
- 在CD中长期使用risankizumab的现实数据有限.
研究的目的:
- 为了评估risankizumab在CD患者的大队伍中的长期有效性和安全性.
- 为了比较ustekinumab经验和ustekinumab先验患者的结果.
- 为了确定在一年内无类固醇临床缓解的预测因素.
主要方法:
- 在CD患者开始使用risankizumab的临床结果的前性监测.
- 使用哈维-布拉德肖指数,C反应蛋白和便calprotectin评估疾病活动.
- 对临床缓解和无类固醇缓解率在12,26和52周的分析.
主要成果:
- 134名患者被纳入有效性分析; 52%的患者曾经使用过乌斯捷尼努马布.
- 52周临床缓解率为54%,无类固醇缓解率为50%.
- 在 ustekinumab 经验和先前的患者之间,缓解率没有统计学上显著的差异.
结论:
- 瑞桑基祖马布在现实CD群体中表现出持续的有效性和有利的安全性.
- 之前的乌斯特基努马布治疗并没有对Risankizumab实现无类固醇缓解的几率产生负面影响.
- 这项研究支持瑞桑基祖马布作为各种CD患者群体的可行长期治疗选择.
相关概念视频
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
01:30Inflammatory Bowel Disease II: Crohn's Disease
189
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
189
01:29Drugs for Treatment of Ulcerative Colitis in IBD
124
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
124
01:21Drugs for Treatment of Constipation-Predominant IBS
139
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
139